Robert Jacobson
Colon & Rectal Surgery · Dallas, TXNPI 1205915378
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $94,056 of the $125,102 with a category attached, or 75.2%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 97.5% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2023 at $54,038 and has fallen 55.5% since, to $24,042 in 2025. Among colon & rectal surgery clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $356.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$122K
- AbbVie$862
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$626
- Merck$276
- Braintree Laboratories, Inc.$231
- Shire North American Group Inc$186
- plus $1K from 20 others
What the payments were for
- Consulting fees$10,6829%
- Speaking & faculty fees$94,05675%
- Travel & lodging$14,11011%
- Food & beverage$6,1295%
- Education$190%
- Gifts$1070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 166 | $121,913 |
| AbbVie(2 entities) | 48 | $862 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 36 | $626 |
| Merck | 19 | $276 |
| Braintree Laboratories, Inc. | 11 | $231 |
| Shire North American Group Inc | 15 | $186 |
| THD America, Inc. | 2 | $159 |
| Mallinckrodt Enterprises LLC | 8 | $133 |
| Johnson & Johnson(2 entities) | 6 | $130 |
| Tetraphase Pharmaceuticals, Inc. | 6 | $91 |
| Medtronic(2 entities) | 4 | $80 |
| Axonics, Inc. | 4 | $64 |
| Davol Inc. | 3 | $58 |
| Ferring Pharmaceuticals Inc. | 3 | $48 |
| Mallinckrodt Hospital Products Inc. | 3 | $45 |
| Acell, Inc. | 3 | $39 |
| Pfizer | 3 | $35 |
| Innovation Technologies Inc | 1 | $16 |
| W. L. Gore & Associates, Inc. | 1 | $15 |
| Acacia Pharma Inc | 1 | $15 |
| KCI USA, Inc. | 1 | $15 |
| Prescient Surgical | 1 | $14 |
| QOL Medical, LLC | 3 | $14 |
| Integra Lifesciences Corporation | 1 | $13 |
| Covidien LP | 1 | $13 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GATTEX$115,491
- SUPREP BOWEL PREP$107
How this compares
$125,102 in reported general payments places this provider in the 95th percentile of 200 colon & rectal surgery providers in Texas.
Other colon & rectal surgery in Dallas
- Katerina WellsDallas$83K
- Anand LodhaDallas$40K
- Roberto Rodriguez-RuesgaDallas$38K
- Michael PendolaDallas$21K
- Anthony MacalusoDallas$20K
- Sarah StringfieldDallas$19K
- Zachary RobertsDallas$17K
- Edward FrankoDallas$13K
- Lai XueDallas$13K
- Nathaniel NgDallas$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.